Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis

Respiratory Investigation

Volumn 53, Issue 2, 2015, Pages 73-81

  Tajiri, Morihiro ^a   Okamoto, Masaki ^a   Fujimoto, Kiminori ^a   Johkoh, Takeshi ^b   Ono, Junya ^c   Tominaga, Masaki ^a   Azuma, Koichi ^a   Kawayama, Tomotaka ^a   Ohta, Shoichiro ^d   Izuhara, Kenji ^d   Hoshino, Tomoaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^c SHINO TEST CORPORATION   (Japan)

^d SAGA UNIVERSITY   (Japan)

Author keywords

Biomarker; High resolution computed tomography; Idiopathic pulmonary fibrosis; Periostin

Indexed keywords

BIOLOGICAL MARKER; CYCLOSPORIN A; LACTATE DEHYDROGENASE; PREDNISOLONE; PROTEIN KL 6; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GENERAL ASPECTS OF DISEASE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HONEYCOMBING SCORE; HUMAN; MALE; MIDDLE AGED; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME; TIME TO EVENT; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; IDIOPATHIC PULMONARY FIBROSIS; IMAGE ENHANCEMENT; TIME FACTOR;

AGED; BIOMARKERS; CELL ADHESION MOLECULES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOGRAPHIC IMAGE ENHANCEMENT; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84924765438     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2014.12.003     Document Type: Article

References (35)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543-548.
3. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531-537.
4. du Bois R.M., Albera C., Bradford W.Z., et al. 6-minute walk distance is an independent predictor of mortality in patients wth idiopathic pulmonary fibrosis. Eur Respir J 2014, 43:1421-1429.
5. Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993, 148:637-642.
6. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006, 11:164-168.
7. Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012, 50:3-13.
8. Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care 1995, 152(6 Pt 1):1860-1866.
9. Greene KE, King TE, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002, 19:439-446.
10. Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 164:193-196.
11. Sumikawa H, Johkoh T, Fujimoto K, et al. Usual interstitial pneumonia and nonspecific interstitial pneumonia: correlation between CT findings at the site of biopsy with pathological diagnoses. Eur J Radiol 2012, 81:2919-2924.
12. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008, 177:433-439.
13. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. 1998, 157:1063-1072.
14. Fujimoto K, Taniguchi H, Johkoh T, et al. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol 2012, 22:83-92.
15. Ichikado K, Suga M, Müller NL, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med 2002, 165:1551-1556.
16. Oka T, Xu J, Kaiser RA, et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res 2007, 101:313-321.
17. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 2009, 66:2219-2230.
18. Fujimoto K, Kawaguchi T, Nakashima O, et al. Periostin, a cellular matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma. Oncol Rep 2011, 25:1211-1216.
19. Oku E, Kanaji T, Takata Y, et al. Periostin and bone marrow fibrosis. Int J Hematol 2008, 88:57-63.
20. Yamaguchi Y, Ono J, Masuoka M, et al. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol 2013, 168:717-725.
21. Ishida A, Ohta N, Suzuki Y, et al. Expression of pendrin and periostin in allergic rhinitis and chronic rhinosinusitis. Allergol Int 2012, 61:589-595.
22. Shiraishi H, Masuoka M, Ohta S, et al. Periostin contributes to the pathogenesis of atopic dermatitis by inducing TSLP production from keratinocytes. Allergol Int 2012, 61:563-572.
23. Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006, 118:98-104.
24. Hayashi N, Yoshimoto T, Izuhara K, et al. T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-gamma and IL-13 production. Proc Natl Acad Sci USA 2007, 104:14765-14770.
25. Uchida M, Shiraishi H, Ohta S, et al. Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol 2012, 46:677-686.
26. Okamoto M, Hoshino T, Kitasato Y, et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 2011, 37:1119-1127.
27. Naik PK, Bozyk PD, Bently JK, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012, 303:1046-1056.
28. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.
29. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176:636-643.
30. Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012, 141:222-231.
31. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009, 136:1364-1370.
32. Horowitz JC, Thannickal VJ. Idiopathic pulmonary fibrosis: new concepts in pathogenesis and implications for drug therapy. Treat Respir Med 2006, 5:325-342.
33. King TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001, 164:1025-1032.
34. Kaarteenaho-Wiik R, Mertaniemi P, Sajanti E, et al. Tenascin is increased in epithelial lining fluid in fibrotic lung disorders. Lung 1998, 176:371-380.
35. Kaarteenaho-Wiik R, Tani T, Sormunen R, et al. Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. Am J Respir Crit Care Med 1996, 154:511-518. (a).